GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a). It stimulates pulsatile GH release from the pituitary while maintaining physiological feedback controls. It is one of the earliest GH-releasing peptides developed and is notable for strong appetite stimulation via ghrelin receptor activation. Beyond endocrine effects, GHRP-6 exhibits cytoprotective properties through the CD36 receptor, with preclinical data showing cardioprotective, neuroprotective, and anti-fibrotic effects.
Category: Growth Hormone Secretagogue. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only / Not approved for human use
GHRP-6 functions as a synthetic ghrelin mimetic by binding to GHS-R1a in the pituitary and hypothalamus, triggering pulsatile GH release and raising IGF-1 levels. Unlike continuous GH administration, GHRP-6 maintains physiological feedback: as GH and IGF-1 rise, endogenous somatostatin increases…
Research base: 0 registered clinical trials and 19 indexed publications reference GHRP-6.
Safety considerations: Intense hunger due to ghrelin receptor activation (more pronounced than other GH secretagogues); Transient mild increases in cortisol and ACTH (typically not clinically significant); Water retention and bloating reported.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
Related peptides: Ipamorelin, CJC-1295, Sermorelin.
Compare: GHRP-6 vs Ipamorelin, GHRP-6 vs CJC-1295, GHRP-6 vs Sermorelin.
GHRP-6 strongly activates the ghrelin receptor (GHS-R1a), which is the primary appetite-stimulating receptor. This effect is more pronounced than with GHRP-2 or ipamorelin, which are more selective.
GHRP-6 is less selective: it raises GH but also increases cortisol, prolactin, and appetite significantly. Ipamorelin is more selective for GH release with fewer side effects. GHRP-6 may be preferred when appetite stimulation is desired.
Yes. Studies show synergistic effects when GHRP-6 is combined with GHRH (e.g., CJC-1295 or Mod GRF 1-29), producing GH responses greater than either alone. This synergism is preserved in most patient populations.
Yes. WADA prohibits all growth hormone secretagogues and releasing peptides.
Beyond GH release, GHRP-6 interacts with the CD36 receptor on immune and muscle cells, activating PI3K/Akt survival pathways. This explains preclinical observations of cardioprotection, neuroprotection, and tissue repair benefits, though these have not been validated in humans.